Pfizer Inc and BioNTechon, on Wednesday, reported results from an initial laboratory study showing that serum antibodies induced by the Pfizer-BioNTech COVID-19 vaccine neutralised the Omicron variant after three doses.
“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine’’ said Albert Bourla, Pfizer’s chief executive.
The companies noted that these results are preliminary and they will continue to collect more laboratory data and evaluate real-world effectiveness.
